-$0.05 Earnings Per Share Expected for Sesen Bio, Inc. (NASDAQ:SESN) This Quarter

Brokerages expect Sesen Bio, Inc. (NASDAQ:SESNGet Rating) to report earnings per share of ($0.05) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Sesen Bio’s earnings. Sesen Bio posted earnings of ($0.35) per share in the same quarter last year, which indicates a positive year over year growth rate of 85.7%. The business is expected to issue its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that Sesen Bio will report full-year earnings of ($0.33) per share for the current year, with EPS estimates ranging from ($0.46) to ($0.19). For the next year, analysts expect that the firm will post earnings of ($0.27) per share, with EPS estimates ranging from ($0.35) to ($0.19). Zacks’ earnings per share calculations are a mean average based on a survey of analysts that follow Sesen Bio.

Sesen Bio (NASDAQ:SESNGet Rating) last announced its quarterly earnings data on Monday, February 28th. The company reported $0.04 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.07) by $0.11.

Several research analysts have commented on the stock. Zacks Investment Research upgraded shares of Sesen Bio from a “sell” rating to a “hold” rating in a report on Friday. StockNews.com initiated coverage on shares of Sesen Bio in a report on Thursday, March 31st. They issued a “hold” rating for the company.

Shares of Sesen Bio stock traded up $0.01 during trading on Monday, hitting $0.51. The stock had a trading volume of 1,986,289 shares, compared to its average volume of 2,111,481. The business has a fifty day moving average of $0.64 and a two-hundred day moving average of $0.83. Sesen Bio has a fifty-two week low of $0.50 and a fifty-two week high of $6.04.

Several hedge funds have recently bought and sold shares of SESN. Morgan Stanley boosted its holdings in shares of Sesen Bio by 3,442.5% during the second quarter. Morgan Stanley now owns 190,446 shares of the company’s stock worth $880,000 after purchasing an additional 185,070 shares during the period. Royal Bank of Canada boosted its holdings in shares of Sesen Bio by 9,763.3% during the second quarter. Royal Bank of Canada now owns 11,836 shares of the company’s stock worth $55,000 after purchasing an additional 11,716 shares during the period. Bank of America Corp DE boosted its holdings in shares of Sesen Bio by 213.1% during the second quarter. Bank of America Corp DE now owns 35,321 shares of the company’s stock worth $163,000 after purchasing an additional 24,041 shares during the period. Invesco Ltd. acquired a new stake in Sesen Bio in the second quarter valued at approximately $337,000. Finally, Parametric Portfolio Associates LLC acquired a new stake in Sesen Bio in the second quarter valued at approximately $388,000. Institutional investors and hedge funds own 24.79% of the company’s stock.

About Sesen Bio (Get Rating)

Sesen Bio, Inc, a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. Its lead product candidates include Vicineum, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment of bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer; to treat non-muscle invasive carcinoma in situ of the bladder in patients previously treated with BCG; and for the treatment of squamous cell carcinoma of the head and neck, as well as VB6-845d, a product candidate for use in the treatment of various types of an anti-epithelial cell adhesion molecule-positive solid tumors.

Featured Articles

Get a free copy of the Zacks research report on Sesen Bio (SESN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Sesen Bio (NASDAQ:SESN)

Receive News & Ratings for Sesen Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sesen Bio and related companies with MarketBeat.com's FREE daily email newsletter.